Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
LARK$32.00-0.63(-1.93%)Landmark Bancorp, Inc. Declares Cash Dividend of $0.21 Per Share and 5% Stock Dividend[2:12:00 PM ET]OMC$79.07-3.61(-4.37%)Omnicom Named a Leader in IDC MarketScape: Worldwide AI-Enabled Adobe Professional Services 2026 Vendor Assessment Omnicom (NYSE: OMC), the world's leading marketing and sales company, today announced it has been named a Leader in the IDC MarketScape: Worldwide...[2:01:00 PM ET]GIII$29.850.00(0.00%)WHP Global, G-III Apparel Group and I.T Group Announce Partnership to Accelerate Marc Jacobs Growth in Greater China WHP Global and G-III Apparel Group, Ltd. (NasdaqGS: GIII) today announced a partnership with I.T Group, a leading omnichannel fashion retailer in...[1:48:00 PM ET]EMTRF$1.35+0.15(+12.44%)Element 29 Announces Grant Of Stock Options and Deferred Share Units[1:48:00 PM ET]ELEK$0.00-0.00(-18.37%)A New Frontier for American Lithium: Elektros (OTC: ELEK) Evaluates Potential Upstate New York Opportunity as Domestic Battery and Critical-Mineral Supply Chains Gain Attention[1:45:00 PM ET]PFE$29.78-0.26(-0.85%)Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting[1:41:00 PM ET]MT$59.24-0.19(-0.32%)Notifications of transaction in ArcelorMittal shares – BlackRock[1:30:29 PM ET]NXST$164.14-3.20(-1.91%)TEGNA Recruits Seasoned Television Executive Mellynda Hartel to Lead Florida Stations[1:30:00 PM ET]ELEK$0.00-0.00(-18.37%)Santa Claus Comes Early to Wall Street: Elektros (OTC: ELEK) Explores an All-American Lithium Opportunity Near Canada as U.S. Battery and Defense Supply Chains Take Center Stage[1:26:00 PM ET]LLY$1,280.56+7.10(+0.56%)Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades[1:12:25 PM ET]

CTOR · NASDAQ

Citius Oncology, Inc.

$0.66 +0.08 (+13.89%)

Company overview

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
Market cap
$61.4M
Employees
285
Headquarters
New York City, NY
Website
citiusonc.com
CEO
Leonard L. Mazur
Listed
December 8, 2022
P/E
-1.38
Dividend yield
0.00%

Company financials

Revenue
$5.6M
Gross profit
$4.5M
Operating income
-$43.5M
EBITDA
-$42.9M
Net income
-$42.5M
EPS
-$0.47
Total assets
$101M
Total debt
$3.8M
Gross margin
80.07%
Net margin
-757.57%
Earnings yield
-72.31%

Price chart

0.480.660.831.011.18
CTOR 1D NASDAQ O0.72H0.72L0.51C0.58-0.12 (-17.16%)Vol70.53K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Type
Ticker Type Headline Source Published
CTORCitius Oncology, Inc. Press release Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 Citius Oncology, Inc. PR Newswire
CTORCitius Oncology, Inc. Press release Citius Pharmaceuticals to Participate in October 2026 Investor Conferences Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and... PR Newswire
CTORCitius Oncology, Inc. Stock news Citius Pharmaceuticals to Participate in September 2026 Investor Conferences PRNewsWire
CTORCitius Oncology, Inc. Stock news Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6% – Here’s What Happened Defense World
CTORCitius Oncology, Inc. Press release Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Ships First International Order of LYMPHIR™ to Europe PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PRNewsWire
CTORCitius Oncology, Inc. Legal SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) PRNewsWire
CTORCitius Oncology, Inc. Stock news Market Today: GDP Jumps, S&P Record; Novo Nordisk (NVO) Pill OK GuruFocus
CTORCitius Oncology, Inc. Press release Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules PRNewsWire
CTORCitius Oncology, Inc. Press release Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PRNewsWire
See more
FAQ

Questions about Citius Oncology, Inc.

What does Citius Oncology, Inc. do?
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
What is CTOR's market cap?
Citius Oncology, Inc. (CTOR) is a listed stock with a live quote. The latest market cap on this page is $61.4M.
Where is Citius Oncology, Inc. headquartered?
Citius Oncology, Inc. is headquartered in New York City, NY.
How do I get CTOR news from the API?
Call GET /v1/news?tickers=CTOR. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does CTOR news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CTOR, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the CTOR price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs